Larimar Reports Results, Advances Nomlabofusp Toward FDA Filing
BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) reported fourth-quarter and full-year 2025 financial results while advancing its lead candidate nomlabofusp toward a planned FDA filing for the treatment …
Larimar Reports Results, Advances Nomlabofusp Toward FDA Filing Read More